Ford, Hugo, Marshall, A. (Andrea), Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda Y., Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary W., Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M. and Dunn, Janet A. (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial. The Lancet Oncology, Volume 15 (Number 1). pp. 78-86. doi:10.1016/S1470-2045(13)70549-7 ISSN 1470-2045.

Preview

Text WRAP_Dunn_1-s2.0-S1470204513705497-main.pdf - Published Version Available under License Creative Commons Attribution. Download (448Kb) | Preview

Request Changes to record.

Abstract

Background:
Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum and fluoropyrimidines has not shown benefits in health-related quality of life (HRQoL). We assessed whether the addition of docetaxel to active symptom control alone can improve survival and HRQoL for patients.

Methods:
For this open-labelled, multicentre trial, we recruited patients aged 18 years or older from 30 UK centres. Patients were eligible if they had an advanced, histologically confirmed adenocarcinoma of the oesophagus, oesophagogastric junction, or stomach that had progressed on or within 6 months of treatment with a platinum-fluoropyrimidine combination. Patients could have an Eastern Cooperative Oncology Group performance status of 0–2. We randomly assigned patients using a central, computerised minimisation procedure to receive docetaxel plus active symptom control, or active symptom control alone (1:1; stratified by disease status, disease site, duration of response to previous chemotherapy, and performance status). Docetaxel was given at a dose of 75 mg/m2 by intravenous infusion every 3 weeks for up to six cycles. The primary endpoint was overall survival, analysed by intention to treat. This is the report of the planned final analysis. This study is an International Standardised Randomised Controlled Trial, number ISRCTN13366390.

Findings:
Between April 21, 2008, and April 26, 2012, we recruited 168 patients, allocating 84 to each treatment group. After a median follow-up of 12 months [IQR 10–21]) and 161 (96%) deaths (80 in the docetaxel group, 81 in the active symptom control group), median overall survival in the docetaxel group was 5·2 months (95% CI 4·1–5·9) versus 3·6 months (3·3–4·4) in the active symptom control group (hazard ratio 0·67, 95% CI 0·49–0·92; p=0·01). Docetaxel was associated with higher incidence of grade 3–4 neutropenia (12 [15%] patients vs no patients), infection (15 [19%] patients vs two [3%] patients), and febrile neutropenia (six [7%] patients vs no patients). Patients receiving docetaxel reported less pain (p=0·0008) and less nausea and vomiting (p=0·02) and constipation (p=0·02). Global HRQoL was similar between the groups (p=0·53). Disease specific HRQoL measures also showed benefits for docetaxel in reducing dysphagia (p=0·02) and abdominal pain (p=0·01).

Interpretation:
Our findings suggest that docetaxel can be recommended as an appropriate second-line treatment for patients with oesophagogastric adenocarcinoma that is refractory to treatment with platinum and fluoropyrimidine.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions:	Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Esophagus -- Cancer , Clinical trials -- Great Britain
Journal or Publication Title:	The Lancet Oncology
Publisher:	The Lancet Publishing Group
ISSN:	1470-2045
Official Date:	January 2014
Dates:	Date Event January 2014 Published
Volume:	Volume 15
Number:	Number 1
Page Range:	pp. 78-86
DOI:	10.1016/S1470-2045(13)70549-7
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access (Creative Commons)
Date of first compliant deposit:	26 December 2015
Date of first compliant Open Access:	26 December 2015
Funder:	Cancer Research UK (CRUK), Cambridge University Hospitals NHS Foundation Trust , National Institute for Health Research (Great Britain) (NIHR), University College London Hospitals Charities, University College, London, Wellcome Trust (London, England), National Institute for Health Research (Great Britain) (NIHR)
Grant number:	C21276/A12372, CRUK/07/013 (CRUK)

Request changes or add full text files to a record

Repository staff actions (login required)

View Item

Downloads